Supply Information

Information on the availability of Mounjaro® (tirzepatide) in Australia

Update 26 March 2025

Eli Lilly Australia (Lilly) introduced the multi-use Mounjaro KwikPen presentation in 2024 to resolve the supply situation in Australia. All doses of Mounjaro KwikPen remain available and Lilly is committed to ongoing replenishment of Mounjaro KwikPen in all its doses.

Lilly has made significant investments and expansion in manufacturing around the world, allowing us to dramatically increase our capacity in the coming months and years. We remain committed to ensuring our medicines can reach those who need them.

For patients

In the instance that a dose of Mounjaro is missed, patients should consult their doctor immediately. Patients must always follow the instructions for use contained in the Mounjaro KwikPen Consumer Medicine Information (1) or Mounjaro Vial Consumer Medicine Information (2).

For prescribers and pharmacists

If you require additional medical or scientific information about Mounjaro, please contact Lilly’s Medical Information team on 1800 454 559 / 1800 4 LILLY. Operating hours are Monday to Friday, 9am – 5pm AEDT.

References

  1. Mounjaro KwikPen Consumer Medicine Information. Available at: https://rss.medsinfo.com.au/ly/cmi.cfm?product=lycmounk10824. Accessed March 2025.

  2. Mounjaro Vial Consumer Medicine Information. Available at: https://rss.medsinfo.com.au/ly/cmi.cfm?product=lycmouna10823. Accessed March 2025.

Mounjaro® is a registered trademark of Eli Lilly and Company.

Eli Lilly Australia Pty Limited, Level 9, 60 Margaret Street, Sydney, NSW 2000, Australia. ABN 39 000 233 922. Prepared March 2025. PP-TR-AU-0339.